Drug Guidance
View all drug guidances and its details here.
196 articles
1 April 2026
Blinatumomab for treating relapsed or refractory B-precursor acute lymphoblastic leukaemia
Condition
Blood and Immune System
Cancer
Drug guidance
1 April 2026
Update of MOH List of Subsidised Drugs to include treatments for various cancer conditions
Condition
Cancer
Drug guidance
1 April 2026
Review of cancer drugs for acute lymphoblastic leukaemia
Condition
Blood and Immune System
Cancer
Drug guidance
1 April 2026
Review of cancer drugs for previously treated advanced gastric cancer
Condition
Cancer
Gastrointestinal tract
Drug guidance
1 April 2026
Review of cancer drugs for treating advanced urothelial carcinoma
Condition
Cancer
Urological
Drug guidance
1 April 2026
Nivolumab for treating gastroesophageal cancers
Condition
Cancer
Gastrointestinal tract
Drug guidance
1 April 2026
Nirmatrelvir and ritonavir combination for treating mild-to-moderate COVID-19
Condition
Infections
Drug guidance
6 February 2026
Omalizumab biosimilar for treating inflammatory conditions
Condition
Blood and Immune System
Respiratory
-
Drug Guidance
6 February 2026
Biologics as add-on therapy for severe asthma
Condition
Respiratory
Drug guidance
6 February 2026
Ustekinumab biosimilar for treating inflammatory conditions
Condition
Gastrointestinal tract
-
Drug guidance